The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer

被引:159
作者
Bosco, Emily E.
Wang, Ying
Xu, Huan
Zilfou, Jack T.
Knudsen, Karen E.
Aronow, Bruce J.
Lowe, Scott W.
Knudsen, Erik S.
机构
[1] Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Dept Cell Biol, Cincinnati, OH 45267 USA
[2] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA
[3] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA
关键词
D O I
10.1172/JCI28803
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of human cancers and is aberrant in one-third of all breast cancers. RB regulates G(1)/S-phase cell-cycle progression and is a critical mediator of antiproliferative signaling. Here the specific impact of RB deficiency on E2F-regulated gene expression, tumorigenic proliferation, and the response to 2 distinct lines of therapy was investigated in breast cancer cells. RB knockdown resulted in RB/E2F target gene deregulation and accelerated tumorigenic proliferation, thereby demonstrating that even in the context of a complex tumor cell genome, RB status exerts significant control over proliferation. Furthermore, the RB deficiency compromised the short-term cell-cycle inhibition following cisplatin, ionizing radiation, and antiestrogen therapy. In the context of DNA-damaging agents, this bypass resulted in increased sensitivity to these agents in cell culture and xenograft models. In contrast, the bypass of antiestrogen signaling resulted in continued proliferation and xenograft tumor growth in the presence of tamoxifen. These effects of aberrations in RB function were recapitulated by ectopic E2F expression, indicating that control of downstream target genes was an important determinant of the observed responses. Specific analyses of an RB gene expression signature in 60 human patients indicated that deregulation of this pathway was associated with early recurrence following tamoxifen monotherapy. Thus, because the RB pathway is a critical determinant of tumorigenic proliferation and differential therapeutic response, it may represent a critical basis for directing therapy in the treatment of breast cancer.
引用
收藏
页码:218 / 228
页数:11
相关论文
共 58 条
[1]   GENETIC INSTABILITY AS A CONSEQUENCE OF INAPPROPRIATE ENTRY INTO AND PROGRESSION THROUGH S-PHASE [J].
ALMASAN, A ;
LINKE, SP ;
PAULSON, TG ;
HUANG, LC ;
WAHL, GM .
CANCER AND METASTASIS REVIEWS, 1995, 14 (01) :59-73
[2]  
[Anonymous], CLIN CANC RES S
[3]   Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses [J].
Bhattacharjee, A ;
Richards, WG ;
Staunton, J ;
Li, C ;
Monti, S ;
Vasa, P ;
Ladd, C ;
Beheshti, J ;
Bueno, R ;
Gillette, M ;
Loda, M ;
Weber, G ;
Mark, EJ ;
Lander, ES ;
Wong, W ;
Johnson, BE ;
Golub, TR ;
Sugarbaker, DJ ;
Meyerson, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) :13790-13795
[4]   Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells [J].
Bindels, EMJ ;
Lallemand, F ;
Balkenende, A ;
Verwoerd, D ;
Michalides, R .
ONCOGENE, 2002, 21 (53) :8158-8165
[5]  
BORG A, 1992, CANCER RES, V52, P2991
[6]   TP53 and breast cancer [J].
Borresen-Dale, AL .
HUMAN MUTATION, 2003, 21 (03) :292-300
[7]   RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult [J].
Bosco, EE ;
Mayhew, CN ;
Hennigan, RF ;
Sage, J ;
Jacks, T ;
Knudsen, ES .
NUCLEIC ACIDS RESEARCH, 2004, 32 (01) :25-34
[8]   E2F target genes: unraveling the biology [J].
Bracken, AP ;
Ciro, M ;
Cocito, A ;
Helin, K .
TRENDS IN BIOCHEMICAL SCIENCES, 2004, 29 (08) :409-417
[9]   RB activation defect in tumor cell lines [J].
Broceño, C ;
Wilkie, S ;
Mittnacht, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (22) :14200-14205
[10]   Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells [J].
Cariou, S ;
Donovan, JCH ;
Flanagan, WM ;
Milic, A ;
Bhattacharya, N ;
Slingerland, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (16) :9042-9046